| Thieme Medical Publishers : Medical Publications | |
| ||
| Ringe Alfacalcidol in Prevention and Treatment of all Major Forms of Osteoporosis and in Renal Osteopathy Table of ContentsContents: 1. Short history of vitamin D 2. Reduced vitamin D-supply and osteoporosis 3. Natural supply of vitamin D 4. Metabolism of vitamin D 5. Distinction between plain vitamin D and active D-analogs 6. Normal and optimal 25-hydroxy-vitamin D levels ? 7. Recommended doses for vitamin D supplementation 8. Active D-metabolites: Differences between alfacalcidol and calcitriol 9. Clinical indications for plain vitamin D in metabolic bone diseases 10. Limitations for plain vitamin D in metabolic bone diseases 11. Metabolism and pharmacological effects of alfacalcidol 12. Rationale to use alfacalcidol in different forms of osteoporosis 13. Effects of alfacalcidol on muscle and other non-osseous target tissues 14. Dosage, adverse events and contraindications of alfacalcidol 15. Indications and clinical evidence for alfacalcidol in osteoporosis 16. Prevention of postmenopausal osteoporosis 17. Alfacalcidol for treatment of established postmenopausal osteoporosis 18. Alfacalcidol in the elderly 19. Alfacalcidol in glucocorticoid-induced osteoporosis 20. Alfacalcidol as a partner for combined treatment regimens 21. Clinical features of renal bone disease 22. Pathogenetic mechanisms of renal bone disease 23. Prevention and treatment of renal bone disease 24. Prevention of bone loss after renal transplantation |
© Thieme Medical Publishers, Inc. 2008 General information: info@thieme.com Technical Comments/Problems: webteam@thieme.com Purchase information (Rest of World): custserv@thieme.de Purchase information (Americas): customerservice@thieme.com Phone: 1-212-760-0888 * Custserv.: 1-800-782-3488 * Fax: 1-212-947-1112 |